Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ligong Nie

Real‐world Data on EGFR/ALK Gene Status and First‐line Targeted Therapy Rate in Newly Diagnosed Advanced Non‐small Cell Lung Cancer Patients in Northern China: A Prospective Observational Study

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Related publications

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China

PLoS ONE
Multidisciplinary
2018English

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2018English

Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced Non-Small Cell Lung Cancer Patients: A Single Center Retrospective Analysis

Lung Cancer: Targets and Therapy
Oncology
2019English

P3.13-22 Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients With EGFR Mutant Non-Small Cell Lung Cancer.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.15-32 Real World EGFR Mutation Profile From 1699 Non-Small Cell Lung Cancer Patients in Eastern China

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.03-007 a Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy